Page 20 - Cipla

Pricing woes force Cipla, Glenmark, Lupin to go slow on US drug pipeline

Companies to focus on complex products as tough competition in generics, customer consolidation impact profits

Cipla gains 7% on healthy operational performance in Q3

The stock surged 7% to Rs 608 after the EBITDA margins in December quarter improved to 20.9% from 18.6% in year ago quarter and 19.7% in previous quarter.

Cipla stands out in a gloomy sector as revenue swells 15% to Rs 16 bn

Improving prospects of US business to drive the company's earnings

Business for posterity

Companies must create value through transformational impact on the planet

Cipla battles perceptions in a new campaign

The pharma major engages directly with patients, addresses social stigma and environmental concerns to expand the brand footprint in respiratory diseases

Cipla shines in gloomy pharma pack, biggest beneficiary of faster approvals

A low base in the US also means lower risks of price erosion, but as the company builds up its product pipeline expect earnings to improve

Cipla gets USFDA nod to market generic version of cancer drug Dacogen

It is indicated for treatment of patients with myelodysplastic syndromes

Cipla's US sales get boost with limited competition drugs

In Oct, it received the nod for a generic version of limited competition drug Renvela, used to treat kidney disease

Cipla gains 3% on final approval for generic Pulmicort Respules

The company has received final approval from the USFDA to market a generic version of Astrazeneca's Pulmicort Respules.

Cipla's consistent margin gains stand out

Sales growth, benefits from operating leverage led to an in-line performance

Cipla hits 52-week high ahead of Q2 results

The stock moved higher to its 52-week high of Rs 661, up 3% on the BSE, ahead of its Q2FY18 results on Tuesday, November 7, 2017

Cipla ring-fences promoter holding

The promoter shareholding is valued at over Rs 16,600 crore

Cipla an outlier among pharma majors

Healthy outlook on strong margins, niche product launches and traction in key regulatory markets

Cipla surges 6% after stellar Q1 on healthy operating performance

Cipla was the largest gainer among Sensex and Nifty50 stocks at 11:01 am

Cipla: Declining India sales lead to a Q1 miss

Margin improvement a silver lining, if sustained, can boost confidence

Cipla Q1 net profit surges 24% to Rs 425 crore

The drug major had posted a net profit of Rs 343.70 cr for the corresponding period in FY17

Cipla's newly launched drug to cure severe malaria in young children

The anti-malaria drug now soon will be available in four sub-Saharan countries

Cipla sharpens focus on core therapies

Cipla, the pharmaceuticals major, is exiting non-core businesses to build a stronger pipeline in its key therapies on offer, of respiratory, oncology and anti-HIV drugs. This comes at a time when it faces pricing pressure in both India and America. The move will mean more capital for key growth areas and reduce investment risk.One step is the decision to scale down the biotechnology business. Last week, Cipla said it would not manufacture biosimilars. It also put on hold an earlier plan for a manufacturing unit in South Africa. The announcement was made after a Rs 62 crore loss in the March quarter.It is, however, not exiting the biotech segment. It will look for in-licensing opportunities and partners for two biosimilar drugs which are under trial.Umang Vohra, chief executive officer, said they now aimed to strengthen business in the core markets (India, the US and South Africa) and core therapies such as respiratory, oncology and anti-HIV drugs. "You will see us doing lot more in ...

Weak domestic sales hurt Cipla in Q4

Sales from this segment account for the largest share in revenue

Margin expansion crucial for Cipla's stock

Cipla continues to strengthen its global footprint. Wednesday's acquisition of Anmarate (Pty) Ltd in South Africa, and Cipla USA entering into a collaboration with MEDRx a few days ago, are a step in this direction. Such moves will help Cipla report healthy topline growth, but analysts say improvement in profitability is equally crucial.The acquisition of Anmarate, which develops and manufactures medicines and medical devices, will add to Cipla's strengths in South Africa, which already contributes about 13 per cent to its revenues. The US collaboration is to take further the development and commercialisation of MRX-4TZT, a tizanidine1 patch for the management of spasticity. This will enhance Cipla's presence in branded specialty space. To bolster the US generic business, Cipla has already completed two acquisitions last year. It is also on course for achieving full year guidance of 20-25 ANDAs (abbreviated new drug applications) having already filed 21 ANDAs during first nine months .